Taken together, Kukoamine A has the potential to inhibit human glioblastoma cell growth and migration in vitro and in vivo through apoptosis induction and epithelial-mesenchymal transition attenuation mediated by downregulating expressions of 5-LOX and C/EBPβ (Fig. 7); it might serve as an effective candidate agent for the treatment and/or prevention of human glioblastoma, and deserve to be investigated further. The gene discussed is CEBPB; the disease is glioblastoma.